×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SAGE – sage therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SAGE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
01:30 pm
sage
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]
11/21
12:32 pm
sage
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]
Low
Report
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]
11/21
12:24 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.
11/21
08:05 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
11/20
01:16 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
11/20
10:50 am
sage
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder [Yahoo! Finance]
Low
Report
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder [Yahoo! Finance]
11/20
08:32 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/20
06:43 am
sage
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo! Finance]
High
Report
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
06:40 am
sage
Form 8-K Sage Therapeutics, Inc. For: Nov 20
High
Report
Form 8-K Sage Therapeutics, Inc. For: Nov 20
11/14
06:15 pm
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: BB BIOTECH AG
Medium
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: BB BIOTECH AG
11/14
04:43 pm
sage
Form 4 Sage Therapeutics, Inc. For: Nov 01 Filed by: Benecchi Christopher
Medium
Report
Form 4 Sage Therapeutics, Inc. For: Nov 01 Filed by: Benecchi Christopher
11/12
04:56 pm
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
11/12
10:35 am
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: FMR LLC
Medium
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: FMR LLC
11/8
02:21 pm
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: BlackRock, Inc.
11/4
03:29 pm
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
11/4
02:11 pm
sage
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/29
SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
13.5%
3/13 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.8%
4/3 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9.3%
12/10 Form 4 Sage Therapeutics, Inc. For: Dec 09 Filed by: IGUCHI KIMI 9.2%
4/19 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. 8.7%
12/5 Sage's oral depression therapy fails in late-stage trial; shares plunge [Reuters (UK)] 8.5%
12/5 SAGE Therapeutics Inc (NASDAQ: SAGE) had its price target lowered by analysts at Guggenheim from $200.00 to $110.00. They now have a "buy" rating on the stock. 7.1%
12/11 Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha] 5.8%
6/27 Sage Therapeutics to Host “Sage FutureCast” Webcast 5.4%
11/1 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.1%
3/13 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.8%
4/3 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9.3%
12/10 Form 4 Sage Therapeutics, Inc. For: Dec 09 Filed by: IGUCHI KIMI 9.2%
4/19 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. 8.7%
12/5 Sage's oral depression therapy fails in late-stage trial; shares plunge [Reuters (UK)] 8.5%
12/5 SAGE Therapeutics Inc (NASDAQ: SAGE) had its price target lowered by analysts at Guggenheim from $200.00 to $110.00. They now have a "buy" rating on the stock. 7.1%
12/11 Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha] 5.8%
6/27 Sage Therapeutics to Host “Sage FutureCast” Webcast 5.4%
11/1 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.1%
TOP News Decliners
12/5
Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? [Yahoo! Finance News]
-59.7%
3/11 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $58.00 price target on the stock. -19.3%
2/27 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $69.00 price target on the stock. -17.4%
3/18 SAGE Therapeutics Inc (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. -12.5%
2/27 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud -12.1%
8/30 Tocqueville Opportunity Is One Of The Best Mid-Cap Funds This Year [Forbes] -6.3%
12/16 Sage: In Need Of Authentic Smudging [Seeking Alpha] -6.0%
3/20 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.4%
3/5 SAGE Therapeutics Inc (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.1%
3/4 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.9%
3/11 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $58.00 price target on the stock. -19.3%
2/27 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $69.00 price target on the stock. -17.4%
3/18 SAGE Therapeutics Inc (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. -12.5%
2/27 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud -12.1%
8/30 Tocqueville Opportunity Is One Of The Best Mid-Cap Funds This Year [Forbes] -6.3%
12/16 Sage: In Need Of Authentic Smudging [Seeking Alpha] -6.0%
3/20 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.4%
3/5 SAGE Therapeutics Inc (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.1%
3/4 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: